drugset / Trial / NCT06886919
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NaSequentialOpen-labelTreatment
Summary
This study is an open label, single arm exploratory clinical trial of IC19 CAR-T cell therapy for refractory systemic lupus erythematosus. Patients who are still in an active state after systemic treatment using the standard treatment regimen specified in the treatment guidelines were selected to receive IC19 CAR-T cell single pulse infusion therapy.
Timeline
- Start
- 2025-03-31
- Primary completion
- 2025-09-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC19 CAR-T | Cell therapy | 1e+08 cells | — |
| Subject | IC19 CAR-T | Cell therapy | 2e+08 cells | — |